MedTrace Logo

Evaluation of Half-Dose Molecular Breast Imaging With Wide Beam Reconstruction Processing

NCT01653964 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2017-09-18

Study results available
· View outcomes & findings →

Summary

The primary objective of this work is to determine if half-dose Molecular Breast Imaging (MBI) performed with 4 mCi Tc-99m sestamibi with or without Wide Beam Reconstruction applied can achieve image quality and diagnostic accuracy non-inferior to that of standard MBI performed with 8 millicurie (mCi) Tc-99m sestamibi.

Conditions

Interventions

DIAGNOSTIC_TEST

Molecular breast imaging

Molecular breast imaging performed with injection of Tc-99m sestamibi and a dedicated gamma camera (Luma Gem, Gamma Medica)

Sponsors & Collaborators

  • Friends for an Earlier Breast Cancer Test

    collaborator UNKNOWN

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Carrie B Hruska, PhD · Mayo Clinic

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01653964 on ClinicalTrials.gov